

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 6/9/2022  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Amphetamines (D/L Differentiation), Urine**

ARUP test code 2014043

**D-Amphetamine** 24000 ng/mL  
Urine  
Reporting Limit: 10 ng/mL  
Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

**L-Amphetamine** 9500 ng/mL  
Urine  
Reporting Limit: 10 ng/mL  
Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

**D-Amphetamine Percent** 71 %  
Urine  
Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

**L-Amphetamine Percent** 28 %  
Urine  
Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

**D-Methamphetamine** None Det ng/mL  
Urine  
Reporting Limit: 10 ng/mL  
Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

**H=High, L=Low, \*=Abnormal, C=Critical**

---

**L-Methamphetamine**

None Det ng/mL

Urine

Reporting Limit: 10 ng/mL

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

---

**D-Methamphetamine Percent**

0.0 %

Urine

D-methamphetamine at more than 20% of the total is considered indicative of a source other than an over-the-counter (OTC) product. A greater than 20% concentration of the D-isomer can result from illicit methamphetamine use, or D-methamphetamine-containing prescription drugs, or from the metabolism of certain prescribed drugs (e.g., benzphetamine)

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

---

**L-Methamphetamine Percent**

0.0 %

Urine

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

Testing performed at NMS Labs, Inc.  
200 Welsh Road  
Horsham, PA 19044-2208  
CLIA 39D0197898

---

**H=High, L=Low, \*=Abnormal, C=Critical**

---

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
D-Amphetamine	23-169-105369	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
L-Amphetamine	23-169-105369	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
D-Amphetamine Percent	23-169-105369	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
L-Amphetamine Percent	23-169-105369	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
D-Methamphetamine	23-169-105369	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
L-Methamphetamine	23-169-105369	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
D-Methamphetamine Percent	23-169-105369	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
L-Methamphetamine Percent	23-169-105369	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-169-105369  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 3 of 3 | Printed: 12/27/2023 1:32:22 PM  
4848